Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.35 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23178869 | 0.89 | SLC18A3 (0.35) | ALDH1A1CARM1PRMT6KDM4EKMT2A | |
| SCHEMBL24701555 | 0.87 | ALDH1A1 (0.36) | ALDH1A1CARM1PRMT6KDM4ECCR5 | |
| SCHEMBL10052290 | 0.86 | CARM1 (0.37) | CARM1PRMT6KDM4ECCR5 | |
| SCHEMBL20233050 | 0.80 | BCHE (0.43) | ALDH1A1CARM1PRMT6 | |
| SCHEMBL22020562 | 0.80 | CYP3A4 (0.35) | KDM4ECYP2D6 | |
| SCHEMBL12713 | 0.80 | BCHE (0.43) | ALDH1A1CARM1PRMT6 | |
| SCHEMBL9925435 | 0.80 | CYP3A4 (0.35) | KDM4ECYP2D6 | |
| SCHEMBL13036991 | 0.80 | BCHE (0.43) | ALDH1A1CARM1PRMT6 | |
| SCHEMBL26345081 | 0.80 | PIK3CD (0.41) | ALDH1A1CARM1PRMT6KDM4EMEN1 | |
| SCHEMBL3431959 | 0.80 | CYP2D6 (0.47) | ALDH1A1CARM1PRMT6CYP2D6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691989-B2 | Macrocyclic indoles as Mcl-1 inhibitors | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
| US-11691989-B2 | Macrocyclic indoles as Mcl-1 inhibitors | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691989-B2 | Macrocyclic indoles as Mcl-1 inhibitors | MCL1, BCL2A1, BCL2L1 | ALDH1A1 370/4885CARM1 481/4885PRMT6 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.